Pertuzumab

Late‑stage results show divarasib superiority in KRAS G12C NSCLC, giredestrant preserves quality of life while improving efficacy, and Tam‑Peli shows robust activity in nasopharyngeal carcinoma.

FDA accepted priority NDA for oral SERD giredestrant as adjuvant in ER‑positive, HER2‑negative stage I–III breast cancer after phase III lidERA showed 30% iDFS risk reduction; PDUFA 30 Nov 2026.